Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more

Recent & Breaking News (NDAQ:MESO)

Mesoblast Receives Ethics Approval to Treat COVID-19 Patients in Australia

GlobeNewswire September 2, 2020

ROSEN, A LEADING NATIONAL LAW FIRM, Continues Investigation of Securities Claims Against Mesoblast Limited; Encourages Investors with Losses in Excess of $100K to Contact the Firm - MESO

Business Wire August 26, 2020

Mesoblast Reports Substantial Operational Progress and Financial Results for the Year Ended June 30, 2020

GlobeNewswire August 26, 2020

Mesoblast 2020 Full Year Financial Results Webcast

GlobeNewswire August 25, 2020

Mesoblast Limited Investors: Company Investigated by the Portnoy Law Firm

GlobeNewswire August 19, 2020

EQUITY ALERT: ROSEN, A TRUSTED AND TOP RANKED FIRM, Announces Investigation of Securities Claims Against Mesoblast Limited; Encourages Investors with Losses in Excess of $100K to Contact the Firm - MESO

GlobeNewswire August 18, 2020

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited and Encourages Investors with Losses of $100,000 to Contact the Firm

Business Wire August 18, 2020

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Mesoblast Limited (MESO) Investigation

ACCESSWIRE IA August 17, 2020

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited and Encourages Investors with Losses of $100,000 to Contact the Firm

Business Wire August 16, 2020

MESO EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Mesoblast Limited - MESO

Business Wire August 16, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

GlobeNewswire August 15, 2020

U.S. FDA Advisory Committee Votes Nine to One in Favor of Remestemcel-L (Ryoncil(TM)) for Efficacy in Children With Steroid-Refractory Acute Graft Versus Host Disease

GlobeNewswire August 14, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

PR Newswire August 13, 2020

Update on Scheduled FDA Advisory Committee Meeting

GlobeNewswire August 11, 2020

Mesoblast Provides Remestemcel-L Update and Quarterly Activity Report

GlobeNewswire July 30, 2020

Executive Leadership Expanded Ahead of First Potential U.S. Product Launch

GlobeNewswire July 24, 2020

FDA Advisory Committee Sets Review Date for Mesoblast's remestemcel-L in Pediatric Steroid-Refractory Acute Graft Versus Host Disease

GlobeNewswire July 21, 2020

Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19

GlobeNewswire July 6, 2020

Remestemcel-L Improves Respiratory and Functional Outcomes in Patients With Inflammatory Lung Disease

GlobeNewswire June 1, 2020

Mesoblast Reports Strong Financial Position and Substantial Operational Progress For the Period Ended March 31, 2020

GlobeNewswire May 27, 2020